Multiple Myeloma Mm clinical trials

Explore recruiting multiple myeloma mm clinical trials.

Recruiting multiple myeloma mm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Multiple Myeloma Mm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Germany, Poland, Czechia, Belgium, France, Greece +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma

Norway

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Dose-Escalation Study of Cevostamab in Participants with Relapsed or Refractory Multiple Myeloma

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma

Belgium, Portugal, Sweden, Italy, France, Poland +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A PHASE II, SINGLE ARM, OPEN LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF CEVOSTAMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED A PRIOR BCMA TARGETING CAR T-CELL THERAPY

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

CO43923 Master Protocol: A Platform Study Evaluating the Safety and Efficacy of Multiple Treatments in Patients with Multiple Myeloma CO43923 Substudy 1: A Non-Interventional Study to Collect Patient-Level Data in Patients with Multiple Myeloma CO43923 Substudy 2 Cevos + Len Treatment: A Phase Ib, Single Arm, Open-Label Study Evaluating the Safety and Efficacy of Cevostamab in Combination with Lenalidomide in Patients with Cytogenetic High-Risk Features Receiving Maintenance Treatment After First Response from Multiple Myeloma Post-Stem Cell Transplant CO43923 Substudy 4 Cevostamab+ Iberdomide Treatment: A Phase Ib, Single Arm, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cevostamab in Combination with Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

Germany, France, Poland, Spain

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Multiple Myeloma Mm trials by city

Multiple Myeloma Mm in Toronto Multiple Myeloma Mm in Vancouver Multiple Myeloma Mm in Montreal Multiple Myeloma Mm in Calgary Multiple Myeloma Mm in Edmonton Multiple Myeloma Mm in Ottawa Multiple Myeloma Mm in Winnipeg Multiple Myeloma Mm in Quebec City Multiple Myeloma Mm in Hamilton Multiple Myeloma Mm in Kitchener Multiple Myeloma Mm in London Multiple Myeloma Mm in Halifax Multiple Myeloma Mm in New York Multiple Myeloma Mm in Los Angeles Multiple Myeloma Mm in Chicago Multiple Myeloma Mm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease